Adeptus Health Inc. (NYSE:ADPT) Files An 8-K Other EventsItem 8.01. Other Information.
(a) Acquisition by Funds Advised by Deerfield Mgmt, L.P. of Loans under Credit Agreement
The Company has been informed that on April 3, 2017, funds advised by Deerfield Mgmt, L.P. (“Deerfield”) acquired the $212.7 million aggregate principal amount of outstanding loans (including the Bridge Loans (as defined below)) under the credit agreement, dated of October 6, 2015, by and among the Company’s subsidiary First Choice ER LLC (the “Borrower”), the guarantors named therein (together with the Borrower, the “Loan Parties”), the lenders named therein and Bank of America, N.A., as administrative agent (as amended, modified, supplemented, increased and extended from time to time, the “Credit Agreement”).
(b) Restructuring of Indebtedness
As previously reported, the Company’s board of directors and management continue to explore various options to restructure its outstanding indebtedness aimed at significantly reducing long-term debt and other financial obligations and creating a sustainable capital structure to position the Company for the future. At March 31, 2017, the aggregate principal amount of the Company’s and its subsidiaries’ outstanding indebtedness was approximately $214.2 million. In connection with the exploration of available debt restructuring alternatives, the Company is engaged in discussions with Deerfield, in its capacity as the majority lender under the Credit Agreement, and certain other creditors (including MPT Operating Partnership, L.P. ("MPT"), with which the Company understands that Deerfield has entered into an agreement in principle regarding master lease facilities) regarding a potential transaction in which Deerfield would provide further bridge capital and extend debtor-in-possession financing to the Company, in connection with a court-supervised restructuring of the Company, its debt and outstanding securities, with an ultimate goal on Deerfield’s part of obtaining control of the Company or key assets thereof, and, following consummation of such series of transactions, operating the Company or such assets. The Company has been informed that, assuming consummation of such transactions, Deerfield intends to fund the operations of the acquired business such that it can continue to provide patients the highest quality care and support its employees, affiliated physicians and partners.
No definitive agreement has been reached to date with Deerfield, MPT or other creditors. The outcome and timing of these discussions cannot be predicted at this time. There can be no assurance that such discussions will result in consummation of any restructuring or, if consummated, as to the terms or structure. As a result of any such restructuring and the manner in which it may be implemented, existing holders of shares of the Company’s common stock are highly unlikely to recover any value on their investment upon consummation of the restructuring. The Company does not expect to announce or comment on developments with respect to any restructuring and related transactions or events until the board of directors has approved a specific transaction or has other reason to comment.
(c) Certain Defaults under Credit Agreement and MPT Leases
As previously reported, on March 7, 2017, the Borrower and certain of its affiliates entered into that certain third amendment (the “Third Amendment”), dated as of March 7, 2017, amending certain terms of the Credit Agreement. to the Third Amendment, certain of the lenders under the Credit Agreement (the “Bridge Lenders”) funded an additional tranche of term loans in the aggregate principal amount of $7.5 million (the “Bridge Loans”).
The Bridge Loans matured unpaid on March 31, 2017. The nonpayment of the Bridge Loans constitutes an event of default under the Credit Agreement that gives the lenders the right to exercise the remedies provided under the Credit Agreement.
The Company is currently in discussions with Deerfield to extend the maturity date of the Bridge Loans, waive the event of default referenced in the previous paragraph and, as mentioned under section (b) above obtain additional bridge financing and debtor-in-possession financing for the pendency of the court-supervised restructuring process. The outcome and timing of these discussions cannot be predicted at this time. There can be no assurance that such discussions will result in extension of the maturity date of the Bridge Loans or the consummation of additional bridge financing and debtor-in-possession financing to the Company and, if consummated, as to the terms thereof.